Liposomal-encapsulated doxorubicin (Myocet; D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study.
OBJECTIVE
We conducted a feasibility study to determine the safety and efficacy of liposome-encapsulated doxorubicin (Myocet) and vinorelbine in previously treated metastatic breast cancer patients.


METHODS
Liposome-encapsulated doxorubicin (30 mg/m2) plus vinorelbine (25 mg/m2) on days 1 and 8, every 3 weeks were given until disease progression, sever toxicity or up to 9 cycles. All patients underwent tumor assessment before enrollment. Patients with a life expectancy longer than 3 months and measurable or assessable disease were eligible.


RESULTS
Twenty-one patients were included. Median number of treatment cycles was 5 (range, 3-9). No complete response was obtained. Stable disease and/or partial response was obtained in 9 patients. Fifteen patients experienced grade 3-4 leukopenia. There was no significant decline in cardiac function. Non-hematological toxicity was tolerable (grade 1-2).


CONCLUSIONS
The association of doxorubicin and vinorelbine has been shown to be feasible in previously treated advanced breast cancer patients. Its efficacy should be tested as first-line therapy in metastatic patients with cardiac co-morbidities.
Poletti
Paola
P
Unità Operativa di Oncologia Medica, Ospedali Riuniti di Bergamo, Bergamo, Italy. ppoletti@ospedaliriuniti.bergamo.it
Bettini
Anna Cecilia
AC
Caremoli
Elena Rota
ER
Labianca
Roberto
R
Tondini
Carlo
C
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D004317:Doxorubicin; D000077235:Vinorelbine